SDS Optic S.A. stock debuts on the NewConnect market

On Tuesday, March 15, 2022, the first listing of SDS Optic S.A. shares took place on the NewConnect market. The company is developing its proprietary inPROBE technology platform for real-time medical diagnostics in oncology, as well as infectious, viral, bacterial, and fungal diseases. A total of 5,026,250 shares of series A, B, and D will be introduced to trading.

See the presentation prepared for investors, shareholders, and those interested in the development of inPROBE technology

SDS Optic S.A. investor presentation 03.2022

The debut was preceded by a private share issuance conducted in the first half of 2021, raising PLN 11 million. Investors acquired a total of 1,100,000 Series D shares, representing 20.7% of the Company's share capital. The funds from this offering were allocated, among other things, to the development of ongoing projects and R&D work aimed at identifying additional application fields for inPROBE technology, as well as to support the process of securing a commercial partner—a professional global M&A advisor experienced in partnership transactions in the medical and pharmaceutical markets.

We are approaching our debut on the NewConnect market, which marks the culmination of the past year of our work and commitment in various areas of the Company's operations. We hope that our presence on the stock exchange will support the Company's further development plans, including the planned international expansion, and will help us reach new business partners. We also believe that the Company will attract a broad group of new investors who will recognize its potential and advantages," says Marcin Staniszewski, President of the Management Board of SDS Optic S.A.

The Lublin-based company SDS Optic S.A. has developed an innovative and globally unique fiber-optic microsensor called inPROBE. It is a biosensor with a high level of sensitivity and specificity, allowing for the biological measurement of the concentration of a specific biomarker or dedicated compound in a patient's body (in vivo testing). The primary area of application that the company is currently focusing on for development and commercialization is the diagnosis and targeted treatment of HER2-positive breast cancer. The technology being developed by SDS Optic offers an alternative diagnostic method to the more time-consuming and invasive traditional biopsy.

While developing the inPROBE technology, we first focused on its application in the diagnosis of HER2 breast cancer. We aim to support the work of diagnostic doctors, speed up the diagnostic process, and also aid in treatment planning. Ultimately, the probe may also help monitor the effectiveness of treatment concerning the administered drug. We are currently finalizing preparations for Phase I of clinical trials, the so-called safety phase, which will last approximately three months. Unfortunately, the pandemic remains an external risk factor that may extend the duration of the safety phase. Nevertheless, we remain optimistic and believe that the inPROBE microsensor will successfully pass these trials, says Professor Magdalena Staniszewska, Scientific Director, and shareholder of SDS Optic S.A.

After the successful completion of clinical trials, the Company intends to obtain CE certification and then carry out the approval procedure for this application field of the microsensor. This will enable its commercialization.

At the turn of the second and third quarters of 2021, the Company successfully conducted toxicological studies of the microsensor in a certified animal research facility adhering to Good Laboratory Practice (GLP) standards. The aim of the study was a detailed analysis of the effects of the microsensor injection, including observation of overall health after injection, hematological tests, biochemical and enzymatic tests, inflammatory markers, as well as pathomorphological and histopathological examinations. The study also assessed the healing rate after injection and the potential risk of device failure (breakage, retention in the body, or issues reaching the target tissues).

Market reports indicate that the compound annual growth rate of the global HER2 molecular diagnostics market from 2019 to 2025 will be 12%, increasing the market value to over $6.4 billion by 2025. In 2019, more than 7.5 million HER2 molecular diagnostic tests were performed, with a total value exceeding $4.1 billion.